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Simpson-Golabi-Behmel syndrome (SGBS) (OMIM 
#312870) is an X-linked overgrowth syndrome 
characterised by distinctive facial features, macro-
somia and multiple congenital abnormalities. [1] This 
is a rare condition, with only about 100 molecularly 
confirmed cases reported in the literature.[2] The clinical picture can 
be difficult to distinguish from other overgrowth conditions, with 
which it shares many overlapping features.[3] This could lead to 
misdiagnosis and therefore under-reporting of SGBS. There have 
been no previous published reports of this condition in South Africa 
(SA).
SGBS was originally delineated by Simpson et al.[4] in 1975, who 
described boys with ‘bulldog-like’ facies. However, it was only 
in 1988 that Neri et al.[5] coined the eponymous term ‘Simpson-
Golabi-Behmel syndrome’, after the original author and those of two 
subsequent articles describing the same phenotype.
Boys with SGBS have pre- or postnatal macrosomia. Their facial 
features are coarse, with hypertelorism, downslanted palpebral 
fissures and a broad nasal bridge.[1] They also have a prominent jaw, 
with macrostomia and macroglossia. A groove in the lower lip or 
tongue is frequently present. The nose is often short and upturned 
and about 25% have a cleft lip or palate.[6] Polydactyly with short, 
broad hands has been described.[7]
Other congenital abnormalities include cardiac defects in 36% 
of affected boys[8] and skeletal problems such as pectus excavatum, 
scoliosis and vertebral abnormalities. Gastrointestinal and renal 
abnormalities can also occur.[1] Common urogenital malformations 
are undescended testes and inguinal hernias, but hypospadias and 
ambiguous genitalia have been reported.[9] The intellectual outcome 
is variable, with some individuals having normal development and 
others exhibiting developmental delay. Speech delay is diagnosed in 
about 50% of affected boys and motor delay in 36%.[6] Hypotonia is 
consistently present and structural brain abnormalities can occur.[6]
Importantly, boys with SGBS have an approximately 7.5% risk of 
developing tumours. The spectrum of tumours observed includes 
Wilms tumour, hepatoblastoma, neuroblastoma, gonadoblastoma, 
hepatocellular carcinoma and medulloblastoma.[10] It is widely accepted 
that this risk is sufficient to warrant regular tumour surveillance.
SGBS is inherited in an X-linked recessive manner. Males manifest 
the condition, whereas females are usually asymptomatic carriers. 
However, females can exhibit some features such as tall stature, coarse 
facies and occasionally intellectual disability.[1]
Two adjacent genes on the X chromosome, GPC3 and GPC4, 
have been implicated in SGBS. GPC3 was the first gene described in 
patients with SGBS. Mutations in this gene have been found in up to 
70% of people with the syndrome.[7,11] There are no known hotspots, 
and a variety of mutations ranging from deletions to point mutations 
can occur in any of the eight exons.[11] Recently, exon duplications 
have also been reported.[2] Intragenic GPC4 mutations have not been 
described in isolation and are usually an extension of a deletion that 
includes GPC3. While there has been a report of a GPC4 duplication 
causing SGBS in a family,[12] this duplication cannot explain the 
mechanism of disease. In subsequent studies no other mutations in 
GPC4 have been identified.[2]
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A clinical and molecular evaluation of two probands with SGBS. A 
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to make the diagnosis, which in turn would lead to early initiation 
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Background. Simpson-Golabi-Behmel syndrome (SGBS) is an X-linked recessive overgrowth syndrome manifesting primarily in boys and 
characterised by macrosomia, distinctive facial features and multiple congenital abnormalities. Although this rare condition is thought to 
be underdiagnosed, making a diagnosis is important as affected boys have a 7.5% risk of developing visceral tumours and surveillance is 
warranted. Mutations in GPC3 are found in up to 70% of boys affected with SGBS.
Objectives. A clinical and molecular investigation of two boys with SGBS, probands B and S, and their mothers. Documentation of the 
clinical phenotype could assist with diagnosis in affected boys and will lead to early initiation of tumour surveillance.
Methods. Hospital folders were reviewed and clinical consultations arranged for both probands and their mothers. Molecular investigations 
initially searched for whole-exon deletions in GPC3 followed by gene sequencing.
Results. The clinical phenotype of both probands was consistent with that previously reported in the literature. The main features pointing 
towards the diagnosis were macrosomia, coarse facial features and macroglossia with a midline groove in the tongue. Proband B developed 
a Wilms tumour. He was found to have a novel mutation causing a premature stop codon.
Conclusions. This research represents the first published report of SGBS in South Africa. Early recognition and confirmation of this 
condition is important in order to institute tumour surveillance and assist families with accurate recurrence risks.
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clinical diagnosis but also offer the option 
of carrier and prenatal testing to family 
members at risk.
Methods
Ethics approval was received from the 
Human Research Ethics Committee of the 
Faculty of Health Sciences, University of 
Cape Town, SA (HREC REF 072/2012). 
Two boys with a clinical diagnosis of SGBS 
attending the genetics clinic at Red Cross 
War Memorial Children’s Hospital in Cape 
Town were identified. These probands 
were designated B and S. Their hospital 
folders were reviewed for history, clinical 
findings and special investigations. Clinical 
consultations were arranged for both boys 
along with their mothers, and pertinent 
clinical features were documented.
The molecular analysis was undertaken in 
the Division of Human Genetics, University 
of Cape Town. DNA was extracted from 
venous blood specimens for both probands 
and their mothers using standard methods. 
This DNA was analysed for whole-exon 
deletions and thereafter for sequence 
abnormalities in GPC3.
The primers selected for the amplification 
of GPC3 coding regions were those reported 
in 2007 by Sakazume et al.[13] Exon 3 was 
analysed with two overlapping sets of primers 
owing to the large size of the coding region.
The exons were amplified in singleplex 
using the polymerase chain reaction (PCR) 
in a 25 µL final reaction volume consisting 
of 100 ng template DNA, 10 pmol of each 
primer, 200 µM of each of the deoxynucleotide 
triphosphates (Bioline, UK) and 0.5 units of 
GoTaq DNA polymerase (Promega, USA). 
Following amplification of this reaction on 
the BioRad T100 thermal cycler (BioRad 
Laboratories, USA), the yield and specificity 
of the resulting fragments were confirmed by 
electrophoresis on a 1.5% (w/v) agarose gel 
prior to direct cycle sequencing.
Sequencing for both probands and their 
respective mothers was performed using 
primers employed for the PCR, with 
subsequent capillary electrophoresis on the 
3130xl Genetic Analyser (Life Technologies, 
USA). The results of the sequencing reaction 
were analysed using SeqMan (DNASTAR, 
USA) software systems. The mutation found 
was investigated using two databases, the 
Leiden Open Variation Database[14] and 





Proband B was evaluated at the age of 
5 years and 9 months. There was no family 
history of intellectual concerns, although 
a maternal cousin had a cardiac lesion and 
bowel problem. No further details were 
known. The boy is his mother’s only child.
Proband B was born prematurely by 
vaginal delivery in the breech position. His 
birth weight was 2 100 g (>90th centile) 
and his head circumference 31 cm (>90th 
centile). Postnatally he required ventilation 
for aspiration pneumonia and had pro-
longed jaundice and a single episode of 
hypo glycaemia.
Proband B demonstrated persistent over -
growth, all his growth parameters consis-
tently measuring above the 90th centile 
with some acceleration of his height and 
head circumference noted. On examination 
proband B had a long face with hypertelorism, 
epicanthic folds and an upturned nose (Fig. 1). 
His nasal bridge was broad. His mouth tended 
to be open and he had macrostomia and 
macroglossia with a grooved tongue and 
prognathism. He also had pectus excavatum 
and a marked lordosis.
He had an atrioseptal defect with pul mo-
nary valve stenosis. Genitourinary malform-
ations including bilateral inguinal hernias, 
undescended testes and hypospadias were 
noted at birth. He was subsequently found to 
have right-sided hydronephrosis secondary to 
pelvoureteric obstruction. At ~6 years of age 
he was diagnosed with a Wilms tumour of 
the left kidney. His developmental milestones 
had all been within the normal range, but he 
had been noted to be hypotonic. At the initial 
review his speech was still slightly difficult to 
comprehend, but the rest of his development 
was appropriate for his age.
Additional investigations revealed a 
normal male karyotype (46,XY) and 13 pairs 
of ribs on the chest radiograph.
Proband B’s mother was a healthy woman 
of normal intellect. She had been diagnosed 
with scoliosis during adolescence, which 
resolved spontaneously. She was tall, and at 
1.81 cm her height plotted above the 97th 
centile. She had a long face with no other 
obvious dysmorphic features.
Proband S
Proband S was evaluated at 4 years and 
2 months of age. As shown in the pedigree 
(Fig. 2), mild intellectual disability was 
present in the family. His mother has asthma, 
but was otherwise in good health during the 
pregnancy.
Proband S had been born via normal 
vertex delivery at term. He had Apgar scores 
of 8 and 9. His birth weight was 3 200 g 
(10th centile) and his head circumference 
33 cm (5th centile). Postnatally he was 
ventilated for apnoea and had phototherapy 
for jaundice.
At the time of examination, proband 
S’s weight was above the 50th centile, his 
height above the 75th centile and his head 
circumference above the 95th centile, 
reflecting growth acceleration. He had a 
coarse face with hypertelorism, downslanted 
Fig. 1. The facial features of proband B, showing 
a broad nasal bridge, an upturned nose and a 
large, grooved tongue. Fig. 2. Pedigree of proband S’s family.
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palpebral fissures, epicanthic folds and an 
upturned nose (Fig. 3). His tongue was 
protruding, macroglossic and had a central 
groove. He also had macrostomia. He was 
mildly hirsute with a low posterior hairline.
Proband S had broad, short fingers with 
bilateral fifth-finger clinodactyly. His toes 
were broad and he had pes planus. He 
had mild lumbar lordosis. He had a patent 
ductus arteriosus with a patent foramen 
ovale that closed spontaneously. There were 
no genitourinary abnormalities. Abdominal 
examination showed hepatomegaly of 2 cm 
below the costal margin, which had been 
stable for several years. He was hypotonic 
and had a developmental quotient of 60, in 
keeping with mild intellectual disability.
Magnetic resonance imaging of his brain 
at 2 years of age showed atrophy and a 
peritrigonal white-matter high signal 
sugges tive of a hypoxic insult at birth. A 
chest radiograph revealed 11 ribs on the 
right and 12 on the left. He had a normal 
male karyotype (46,XY).
At the time of examination, proband S 
had not developed any tumours and was 
attending a special educational needs school.
Proband S’s mother had mild intellectual 
disability. She was functionally independent 
and in employment. Her height was 176 cm 
(above the 97th centile). She had a long 
face, with a high-arched palate. The other 
family members with intellectual disability 
were not available for examination.
Table 1 summarises the clinical features 
observed in the two probands and compares 
them with those frequently described in the 
literature.
Molecular investigations
No exonic deletions were found in GPC3 of 
proband B or proband S.
Sequencing revealed a mutation in exon 
4 of GPC3 in proband  B. This mutation 
consists of a deletion of four nucleotides, 
TAGA, at nucleotide position 1071, 
and an insertion of three nucleotides, 
CTT. This mutation, designated as 
c.1071_1074delinsCTT (Genbank accession 
No. NM_004484.3), causes a frameshift that 
results in a premature stop codon. At a 
protein level, this tetranucleotide deletion 
results in a disruption of the amino acid 
reading frame that causes arginine to be 
replaced by phenylalanine at position 358, 
with a resulting premature stop codon at 
position 373, p.(Arg358Phefs*16). As this 
premature stop codon occurs in exon 4, the 
majority of the coding sequence of GPC3 is 
not translated. This mutation was confirmed 
to be present in proband B’s mother in the 
heterozygous state.
No sequence abnormalities were found in 
proband S or his mother.
Discussion
There are no published data describing 
SGBS in SA. The two boys in this study 
exhibited many of the more common 
features described in SGBS. A limitation 
of this study is that both of the probands 
investigated were of Caucasian ancestry.
The diagnosis of SGBS is not easy to 
make, and there is considerable overlap with 
the other overgrowth syndromes. Equally, 
the facial features may not be apparent in 
infants. In SA, where limited genetic testing 
for these syndromes is available, the clinician 
relies heavily on clinical presentation. Other 
genetic overgrowth conditions that need to 
be considered in the differential diagnosis of 
SGBS include Sotos syndrome and Weaver 
and Perlman syndromes. Although these 
syndromes share some clinical features, it is 
usually possible to distinguish between them. 
The condition that is most often confused with 
SGBS is Beckwith-Wiedemann syndrome 
(BWS). BWS is one of the more common 
overgrowth syndromes and is characterised 
by macrosomia, macroglossia and anterior 
abdominal wall defects. It is important to 
distinguish between these conditions, as 
they have different genetic aetiologies 
and prognoses. An X-linked inheritance 
pattern, rib malformations, nail hypoplasia, 
syndactyly of the second and third fingers 
and supernumerary nipples are indicative 
of a diagnosis of SGBS rather than BWS.[3] 
Omphaloceles are infrequently encountered 
in SGBS and are more suggestive of BWS. 
An additional distinguishing feature is that 
the clinical phenotype and facial features 
associated with SGBS tend to become more 
pronounced with age, whereas they tend to 
normalise in those affected with BWS.[3] 
Despite this, one should remain aware of 
the considerable overlap between these two 
conditions.
Both probands in this study were 
diagnosed with SGBS in early childhood. 
Macrosomia, coarse facial features, macro-
glossia and a grooved tongue were the main 
clinical features leading to the diagnosis, 
supported by the cardiac and skeletal 
Table 1. A comparison of the clinical features of the two probands with those reported 
in the literature[1]
Clinical features Proband B Proband S
Macrosomia Yes No
Macrocephaly Yes Yes
Hypertelorism, epicanthic folds, downslanted palpebral fissures Yes Yes
Redundant skin over glabella No No
Macrostomia Yes Yes
Macroglossia Yes Yes
Midline groove lower lip or tongue Yes Yes
Cleft lip or palate or high, narrow palate No No
Macrognathia Yes No
Congenital heart disease Yes Yes
Conduction defects No No
Diastasis recti/umbilical hernia No No
Diaphragmatic hernia No No
Renal dysplasia/nephromegaly Yes No
Cryptorchidism/hypospadias Yes No
Hand anomalies No Yes
Rib anomalies Yes Yes
Fig. 3. Proband S. A coarse facies, grooved tongue 
and macroglossia were present.
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malformations in both boys and the genito-
urinary anomalies in proband B.
The variability in intellectual outcome 
is also evident in these boys. Proband S 
has a family history of mild intellectual 
disability. His mother and his maternal 
aunt are similarly affected and his maternal 
grandfather and great-aunt were reported 
to have intellectual difficulties too. This 
inheritance pattern could be consistent with 
X-linked inheritance, with females showing 
variable clinical expression. It is, however, 
not the only form of inheritance possible, 
and multifactorial causes for intellectual 
disability also warrant consideration.
Proband B developed a Wilms tumour. 
This tumour is known to be associated with 
SGBS. In a recent review of 63 boys with 
SGBS and a confirmed GPC3 mutation, only 
three had developed a Wilms tumour;[2] in 
this context, proband B represents the fourth 
published case.
Table 2 lists examinations and investi-
gations recommended to monitor for 
tumour development.
Many different mutations in GPC3 have 
been described as causative in SGBS. No 
hotspots for these mutations have been 
identified, but frameshift mutations and 
deletions have been reported on numerous 
occasions. All mutations associated with 
SGBS either remove a start codon or 
introduce a premature stop codon. These 
premature stop codons invariably lead to a 
truncated protein with insufficient cysteine 
residues in the conserved cysteine motif.[11]
Although the specific mutation found 
in proband B has not previously been 
reported, its effect appears to be similar 
to other mutations associated with SGBS. 
The sequence anomaly disrupts the reading 
frame and introduces a premature stop 
codon, resulting in the majority of the 
protein not being translated. The databases 
investigated for this mutation confirmed 
that it is novel.
Proband B’s mother was found to be 
heterozygous for this mutation. Accurate 
counselling regarding the recurrence risk 
for future pregnancies is now possible. 
In any future pregnancy, a male fetus 
will have a 50% chance of being affected 
with SGBS and a female fetus will have 
a 50% chance of being a carrier of this 
mutation. Antenatal diagnosis will be 
available to the mother should she want to 
pursue this option, following confirmation 
of the results in a diagnostic laboratory. 
Testing of male offspring in infancy is 
another option. Testing of a minor would 
be ethically justified, as the result would 
have a direct impact on management with 
tumour surveillance. Cascade screening and 
genetic counselling have also been offered to 
proband B’s family.
No mutation was identified in proband S, 
even though mutations in GPC3 are 
present in up to 70% of individuals with 
SGBS.[7,11] This could be because a gene 
other than GPC3 is responsible for his 
condition. GPC4 is such a candidate owing 
to the discovery of a duplication; however, 
since subsequent studies have failed to 
identify point mutations, other as yet 
unidentified genes should be considered. 
Equally, disruption of GPC3 could have 
been caused by a mechanism not examined 
in this study, such as splicing variations 
or intronic alterations. There have also 
recently been reports in the literature of 
exon duplications in GPC3 causing SGBS. [2] 
This abnormality would not have been 
identified by the methods used in this study 
and represents a limitation of this research. 
It is also possible that proband S does not 
have SGBS, but in fact another genetic 
condition. Nevertheless, based on his 
history and clinical features we believe that 
SGBS remains the most likely diagnosis.
Conclusions
This article represents the first published 
description of SA patients with SGBS, an 
underdiagnosed syndrome. The implications 
of a diagnosis of SGBS relate not only to the 
clinical diagnosis and recurrence risk in the 
family, but also to the predisposition for 
developing tumours.
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0 - 4 years 3-monthly 3 - 4-monthly 4-monthly 4-monthly Annually
4 - 7 years 4-monthly 3 - 4-monthly 6-monthly 6-monthly Annually
>7 years Biannually Annually Annually Annually Annually
βHCG = beta-human chorionic gonadotrophin; VMA = vanillylmandelic acid; HVA = homovanillic acid. 
